Clinical Trials · NCT07221214
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Enrollment
- 200
- Start date
- Apr 2026
- Locations
- 1 site, United States
- Primary endpoint
- Average drinks/week past 30 days at 3 months